Results 111 to 120 of about 420,515 (301)
ABSTRACT Background & Aims: Cancer‐associated fibroblasts (CAFs) drive immunosuppression in hepatocellular carcinoma (HCC). However, their metabolic regulation remains poorly defined. We investigated the role of nicotinamide N‐methyltransferase (NNMT) in CAFs. Approach & Results: High NNMT expression in CAF tissues was confirmed by western blotting and
Shounan Lu +20 more
wiley +1 more source
BACKGROUND: Epithelial cell adhesion molecule (EpCAM) is an adhesion molecule which is expressed on the epithelial cells and primarily identified as a tumor marker for carcinoma.
Mehdi Mohammadi
doaj +1 more source
We identified GRIA2 as a critical driver of gastric cancer peritoneal metastasis through in vivo CRISPR screening. Mechanistically, GRIA2‐mediated calcium influx inhibits GSK3β and activates Wnt/β‐catenin signaling, driven by glutamate from cancer‐associated fibroblasts.
Jie Sun +13 more
wiley +1 more source
BZW1 Drives Immune Evasion in Lung Adenocarcinoma via Ferroptosis Suppression
BZW1 attenuates ferroptosis by competitively binding NCOA4 and suppress ferrtinophagy‐mediated iron release. The depletion of BZW1 triggers lipid peroxidation through iron homeostasis. Extracellularly, BZW1 attenuates immunogenic cell death and reinvigorates cytotoxic T‐cell responses.
Linyao Zhao +9 more
wiley +1 more source
High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. [PDF]
IntroductionPrognosis after resection of hepatocellular carcinoma (HCC) is highly variable. Compared to clinicopathologic factors, the use of molecular markers to predict outcome has not been well studied.
Antonia, Ricardo J +10 more
core
Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu +4 more
wiley +1 more source
Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma. [PDF]
BackgroundPlexiform fibromyxoma (PF) is a rare gastric tumor often confused with gastrointestinal stromal tumor. These so-called "benign" tumors often present with upper GI bleeding and gastric outlet obstruction.
Banerjee, Sudeep +9 more
core +1 more source
Gastric cancer‐derived exosomal TAGLN2 is identified as a key mediator of vascular reprogramming, with significantly elevated levels detected in patient serum. Independent of canonical SEMA4D signaling, it nucleates a cytoplasmic TAGLN2/NRP1/SEMA4D ternary complex that dually activates YAP, promoting angiogenesis, vascular dysfunction, and metastasis ...
Shuqi Yu +7 more
wiley +1 more source
Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun +15 more
wiley +1 more source
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård +19 more
wiley +1 more source

